PROTraSarc Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients - A GISAR Sub-study
Latest Information Update: 07 Nov 2024
Price :
$35 *
At a glance
- Drugs Trabectedin (Primary)
- Indications Sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms A GISAR Sub-study; PROTraSarc
- 04 Nov 2024 Status changed from recruiting to completed.
- 15 Nov 2023 Status changed from not yet recruiting to recruiting.
- 25 Sep 2023 New trial record